Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 5,305 matching trials from the live ClinicalTrials.gov search.
Filters: Louisville, Kentucky Clear all
Active, not recruiting Not applicable Interventional

ATTUNE Revision System in the Revision Total Knee Arthroplasty Population

NCT03153475
View directory record Official record
Conditions
Revision Total Knee Arthroplasty
Interventions
ATTUNE Revision Knee System in Revision Total Knee Arthroplasty
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
22 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
16
States / cities
San Diego, California • Denver, Colorado • Fort Collins, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 5:47 PM EDT
Recruiting No phase listed Observational

Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome

NCT07278375
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Not listed
Lead sponsor
HELP for NOWS Consortium
Network
Eligibility
0 Minutes and older
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Wilmington, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

NCT00853827
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Interventions
Placebo, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
54
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 21, 2026, 5:47 PM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

NCT06577441
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
145
States / cities
Berkeley, California • Irvine, California • Orange, California + 120 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain

NCT00376454
View directory record Official record
Conditions
Neuropathic Pain
Interventions
GW493838
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
32
States / cities
Huntsville, Alabama • Hot Springs, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 21, 2026, 5:47 PM EDT
Completed No phase listed Observational

Abbott i-STAT High Sensitivity Troponin I Study

NCT05629572
View directory record Official record
Conditions
Myocardial Infarction
Interventions
i-STAT hs-TnI Cartridge Testing on i-STAT 1 and i-STAT Alinity
Diagnostic Test
Lead sponsor
Abbott Point of Care
Industry
Eligibility
18 Years and older
Enrollment
3,697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
28
States / cities
Chandler, Arizona • San Francisco, California • Stanford, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 5:47 PM EDT
Completed No phase listed Observational

3T MRI CIED Post-Approval Study

NCT02969395
View directory record Official record
Conditions
Cardiac Rhythm Disorder
Interventions
Not listed
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
118
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 115 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 21, 2026, 5:47 PM EDT
Completed No phase listed Observational Results available

QuickFlex Micro Left Ventricular Lead Post Approval Study

NCT01179477
View directory record Official record
Conditions
Heart Failure
Interventions
Implantation of a QuickFlex® μ Model 1258T LV Lead
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
77
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03611751
View directory record Official record
Conditions
Psoriasis
Interventions
BMS-986165, Placebo, Apremilast
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
89
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 21, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

NCT00702702
View directory record Official record
Conditions
Uterine Fibroids, Anemia
Interventions
Proellex 25 mg, Proellex 50 mg, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

NCT00228553
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions
Armodafinil 100 to 250 mg/day
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

NCT00255151
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
100
States / cities
Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT02799602
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

NCT02252172
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab IV, Lenalidomide, Dexamethasone, Daratumumab SC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
737 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
83
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 21, 2026, 5:47 PM EDT
Terminated Phase 4 Interventional Results available

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

NCT03119662
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Visipaque, Placebos
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
17
States / cities
Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 5:47 PM EDT
Active, not recruiting Phase 3 Interventional

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
32
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 5:47 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

NCT02864953
View directory record Official record
Conditions
Brain Edema, Stroke, Acute
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord

NCT00002727
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2016
U.S. locations
218
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

NCT04681066
View directory record Official record
Conditions
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
Interventions
CM-4620 Injectable Emulsion or CM-4620-IE, Placebo
Drug · Other
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

NCT00777231
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Louisville, Kentucky • Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 3 Interventional

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

NCT03891446
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost SR, Standard of Care
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
66
States / cities
Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00070486
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, celecoxib, gemcitabine hydrochloride, zileuton
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
75
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 21, 2026, 5:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implant Placement and Simultaneous Soft Tissue Grafting With Single or Double Layers of Acellular Dermal Matrix

NCT01902056
View directory record Official record
Conditions
Clinical Efficacy
Interventions
One layer allograft, Two layer allograft
Procedure
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 21, 2026, 5:47 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

NCT04083599
View directory record Official record
Conditions
Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
GEN1042, Pembrolizumab, Cisplatin, Carboplatin, 5-FU, Gemcitabine, Nab paclitaxel, Pemetrexed, Paclitaxel
Biological · Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
23
States / cities
Anchorage, Alaska • Los Alamitos, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 21, 2026, 5:47 PM EDT